Wei Ming TanHana Maizuliana SolehanSarah Zulaikha SamadM Firdaus A BakarNor Safiqah SharilNur Ezzaty Mohammad KazminFatimah ZanirahKoon KetSia2024-05-302024-05-3020222022-10-3Tan, W. M., Hana Maizuliana Solehan, Sarah Zulaikha Samad, M Firdaus A Bakar, Nor Safiqah Sharil, Nur Ezzaty Mohammad Kazmin, Fatimah Zanirah, & Koon Ket Sia. (2022). Acute Ischaemic Stroke in a COVID-19 Patient on Baricitinib - A Causal Effect or a Multifactorial Relationship?. Malaysian Journal of Science Health & Technology, 8, 21–24. https://doi.org/10.33102/mjosht.v8i.2652601-00032456-710.33102/mjosht.v8i.265https://mjosht.usim.edu.my/index.php/mjosht/article/view/265https://oarep.usim.edu.my/handle/123456789/15379Vol. 8 (2022): Special Issue on Communicable and Non-Communicable Disease, Multidisciplinary Case ReportsCoronavirus disease 2019 (COVID-19), a multisystemic disorder caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been associated with both venous and arterial thromboses. The hypercoagulable state of the disease poses a challenge to the patient’s management. We herein report a case of acute ischaemic stroke in a COVID-19 patient who had been treated with three days of Baricitinib, an immunotherapy that can potentially augment the thrombotic risks. The case highlights the dilemma faced when initiating immunotherapy in a COVID-19 patient and emphasises the importance of evaluating the patient’s thrombotic risks, balanced against the benefit of immunotherapy, to facilitate the selection of ideal candidates for the immunotherapy.enIschaemic Stroke, COVID-19, Arterial Thrombosis, BaricitinibArticle21248Special Issue